Fig. 1: Overview of baseline sample molecular features with patient outcomes from the iMATRIX-atezo study dataset. | Nature Cancer

Fig. 1: Overview of baseline sample molecular features with patient outcomes from the iMATRIX-atezo study dataset.

From: Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

Fig. 1

‘Other tissue’ indicates metastatic or primary tumors from one of the following: lung, soft tissues, bone, adrenal gland, kidney, brain or unannotated tissue types. Each bar corresponds to a single patient (n = 66 patients). PD, progressive disease. PR, partial response. SD, stable disease. NE, not evaluable.

Back to article page